Aikio M, Odeh H, Wobst H, Lee B, Chan U, Mauna J
Cell Rep. 2025; 44(1):115205.
PMID: 39817908
PMC: 11831926.
DOI: 10.1016/j.celrep.2024.115205.
Watts J, Minden M, Bachiashvili K, Brunner A, Abedin S, Crossman T
Ther Adv Hematol. 2024; 15:20406207241275376.
PMID: 39290981
PMC: 11406655.
DOI: 10.1177/20406207241275376.
Liu W, Ding Z, Tao Y, Liu S, Jiang M, Yi F
Mol Cancer. 2024; 23(1):141.
PMID: 38982480
PMC: 11232239.
DOI: 10.1186/s12943-024-02051-6.
Gao W, Gu K, Ma L, Yang F, Deng L, Zhang Y
Int J Biol Sci. 2024; 20(7):2727-2747.
PMID: 38725857
PMC: 11077359.
DOI: 10.7150/ijbs.90725.
Itonaga H, Mookhtiar A, Greenblatt S, Liu F, Martinez C, Bilbao D
Nat Commun. 2024; 15(1):3415.
PMID: 38649367
PMC: 11035800.
DOI: 10.1038/s41467-024-47689-4.
Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
Bhandari K, Ding W
Int J Mol Sci. 2024; 25(7).
PMID: 38612768
PMC: 11011826.
DOI: 10.3390/ijms25073958.
ERBB1 alleviates secondary brain injury induced by experimental intracerebral hemorrhage in rats by modulating neuronal death via PLC-γ/PKC pathway.
Li B, Wu J, Cao D, Cao C, Zhang J, Li X
CNS Neurosci Ther. 2024; 30(3):e14679.
PMID: 38528842
PMC: 10964039.
DOI: 10.1111/cns.14679.
The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases.
Tao M, Shi Y, Chen H, Li J, Wang Y, Ma X
Mol Biomed. 2024; 5(1):3.
PMID: 38172378
PMC: 10764708.
DOI: 10.1186/s43556-023-00161-z.
PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma.
Kumar D, Jain S, Coulter D, Joshi S, Chaturvedi N
Cancers (Basel). 2023; 15(24).
PMID: 38136401
PMC: 10741595.
DOI: 10.3390/cancers15245855.
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.
Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H
Breast Cancer (Dove Med Press). 2023; 15:785-799.
PMID: 37954171
PMC: 10637385.
DOI: 10.2147/BCTT.S430513.
Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer.
Brobbey C, Yin S, Liu L, Ball L, Howe P, Delaney J
Sci Rep. 2023; 13(1):10752.
PMID: 37400460
PMC: 10318021.
DOI: 10.1038/s41598-023-37706-9.
TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner.
Liu L, Yin S, Gan W
Cancers (Basel). 2023; 15(9).
PMID: 37173967
PMC: 10177089.
DOI: 10.3390/cancers15092501.
The Role of PRMT5 in Immuno-Oncology.
Abe Y, Sano T, Tanaka N
Genes (Basel). 2023; 14(3).
PMID: 36980950
PMC: 10048035.
DOI: 10.3390/genes14030678.
USP7- and PRMT5-dependent G3BP2 stabilization drives de novo lipogenesis and tumorigenesis of HNSC.
Wang N, Li T, Liu W, Lin J, Zhang K, Li Z
Cell Death Dis. 2023; 14(3):182.
PMID: 36878903
PMC: 9988876.
DOI: 10.1038/s41419-023-05706-2.
PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.
Wang K, Luo L, Fu S, Wang M, Wang Z, Dong L
Nat Commun. 2023; 14(1):1011.
PMID: 36823188
PMC: 9950448.
DOI: 10.1038/s41467-023-36708-5.
PRMT5 is a therapeutic target in choroidal neovascularization.
Muniyandi A, Martin M, Sishtla K, Motolani A, Sun M, Jensen N
Sci Rep. 2023; 13(1):1747.
PMID: 36720900
PMC: 9889383.
DOI: 10.1038/s41598-023-28215-w.
Adriamycin induces cardiac fibrosis in mice via PRMT5-mediated cardiac fibroblast activation.
Dong X, Yuan B, Yu S, Liu H, Pan X, Sun J
Acta Pharmacol Sin. 2022; 44(3):573-583.
PMID: 36056082
PMC: 9958096.
DOI: 10.1038/s41401-022-00963-x.
Hepatocyte Growth Factor Enhances Antineoplastic Effect of 5-Fluorouracil by Increasing UPP1 Expression in HepG2 Cells.
Okumura M, Iwakiri T, Yoshikawa N, Nagatomo T, Ayabe T, Tsuneyoshi I
Int J Mol Sci. 2022; 23(16).
PMID: 36012373
PMC: 9409026.
DOI: 10.3390/ijms23169108.
PRMT4-mediated arginine methylation promotes tyrosine phosphorylation of VEGFR-2 and regulates filopodia protrusions.
Hartsough E, Shelke R, Amraei R, Aryan Z, Lotfollahzadeh S, Rahimi N
iScience. 2022; 25(8):104736.
PMID: 35942094
PMC: 9356023.
DOI: 10.1016/j.isci.2022.104736.
Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors.
Brown T, Cao M, Zheng Y
Molecules. 2022; 27(12).
PMID: 35744905
PMC: 9228412.
DOI: 10.3390/molecules27123779.